Drugs giant GSK is scouring the globe for acquisitions and could splash out more than $3 billion to expand in consumer healthcare, over-the-counter medicines, generics and vaccines. Analysts say the company is looking at acquiring Dr Reddy's, the Indian generics firm that has large selling operations in Africa, the Middle East and Latin America. Other targets include Genmab, the Danish biotechnology company, Theravance of the U.S. and Aspen, the South African generics firm. Report